We observe that treatment with FeTPPS (30 mg/kg, i.p.)reduced: the state of brain inflammation and the tissue hurt (histological score), myeloperoxidase activity, nitric oxide production, glial fibrillary acidic protein (GFAP) and pro-inflammatory cytokines expression and apoptosis process. The gene discussed is GFAP; the disease is brain inflammatory disease.